Cellyan Biotechnology Co Ltd (HKPD) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 6-K for Q2 FY2026, filed Mar 18, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HKPD SEC filings page.
Cellyan Biotechnology Co Ltd (HKPD) reported $20.3M in revenue for fiscal year 2025, up 21.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue expansion without earnings conversion defines the business, while positive operating cash flow and minimal leverage shape its financing structure.
In FY2025, revenue reached$20.3M and operating cash flow was$569K , yet net income slipped to-$27K from$1.3M in FY2024; cash conversion held up even as reported profitability disappeared.
Revenue increased
The current ratio rose from 2.5x to 3.0x, increasing the cushion between current assets and current liabilities. Debt-to-equity fell from 0.03x to 0.001x, so balance-sheet expansion was not debt-driven; however, investing cash flow of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cellyan Biotechnology Co Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Cellyan Biotechnology Co Ltd, and counted as zero in the overall score.
Cellyan Biotechnology Co Ltd's revenue surged 21.7% year-over-year to $20.3M, reflecting rapid business expansion. This strong growth earns a score of 88/100.
Cellyan Biotechnology Co Ltd carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.99, Cellyan Biotechnology Co Ltd holds $2.99 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 78/100.
Cellyan Biotechnology Co Ltd has a free cash flow margin of 2.5%, earning a moderate score of 37/100. The company generates positive cash flow after capital investments, but with room for improvement.
Not available for Cellyan Biotechnology Co Ltd, and counted as zero in the overall score.
Cellyan Biotechnology Co Ltd passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Cellyan Biotechnology Co Ltd reported a net loss of $27K while generating $569K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q2 2026.
Cash & Balance Sheet
Cellyan Biotechnology Co Ltd held $191K in cash against $130K in long-term debt as of Q2 2026, with $3.0M of liabilities due within a year.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
HKPD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
HKPD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'266-K | Q4'256-K | Q4'2420-F |
|---|---|---|---|
| Total Assets | $9.6M | $9.4M+8.7% | $8.7M |
| Current Assets | $8.9M | $8.7M+11.9% | $7.8M |
| Cash & Equivalents | $191K | $749K+20.8% | $620K |
| Inventory | $593K | $560K-40.0% | $933K |
| Accounts Receivable | $5.1M | $4.7M+25.9% | $3.7M |
| Goodwill | $90K | $96K+203.0% | $32K |
| Total Liabilities | $4.5M | $4.4M+0.3% | $4.4M |
| Current Liabilities | $3.0M | $2.9M-8.2% | $3.2M |
| Non-Current Liabilities | $1.5M | $1.5M+22.1% | $1.2M |
| Long-Term Debt | $130K | $6K-94.6% | $118K |
| Total Equity | $5.1M | $5.0M+17.3% | $4.3M |
| Retained Earnings | $1.7M | $1.5M-1.8% | $1.5M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
HKPD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
HKPD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Cellyan Biotechnology Co Ltd HKPD | FY2025 | $20.3M | -$27K | -0.1% | $6.8M | 49/100 |
| Scienture Holdings, Inc SCNX | FY2025 | $432K | -$41.5M | N/A | $15.2M | — |
| Petmed Express Inc PETS | FY2026 | $179.0M | -$57.3M | -32.0% | $40.4M | 26/100 |
| Wellgistics Health Inc. WGRX | FY2025 | $23.3M | -$101.3M | N/A | $8.8M | 25/100 |
Where Cellyan Biotechnology Co Ltd Ranks
Frequently Asked Questions
What is Cellyan Biotechnology Co Ltd's annual revenue?
Cellyan Biotechnology Co Ltd (HKPD) reported $20.3M in total revenue for fiscal year 2025. This represents a 21.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cellyan Biotechnology Co Ltd's revenue growing?
Cellyan Biotechnology Co Ltd (HKPD) revenue grew by 21.7% year-over-year, from $16.7M to $20.3M in fiscal year 2025.
Is Cellyan Biotechnology Co Ltd profitable?
No, Cellyan Biotechnology Co Ltd (HKPD) reported a net income of -$27K in fiscal year 2025, with a net profit margin of -0.1%.
How much debt does Cellyan Biotechnology Co Ltd have?
As of fiscal year 2025, Cellyan Biotechnology Co Ltd (HKPD) had $749K in cash and equivalents against $6K in long-term debt.
What is Cellyan Biotechnology Co Ltd's net profit margin?
Cellyan Biotechnology Co Ltd (HKPD) had a net profit margin of -0.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cellyan Biotechnology Co Ltd's return on equity (ROE)?
Cellyan Biotechnology Co Ltd (HKPD) has a return on equity of -0.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cellyan Biotechnology Co Ltd's free cash flow?
Cellyan Biotechnology Co Ltd (HKPD) generated $499K in free cash flow during fiscal year 2025. This represents a 211.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cellyan Biotechnology Co Ltd's operating cash flow?
Cellyan Biotechnology Co Ltd (HKPD) generated $569K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cellyan Biotechnology Co Ltd's total assets?
Cellyan Biotechnology Co Ltd (HKPD) had $9.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cellyan Biotechnology Co Ltd's capital expenditures?
Cellyan Biotechnology Co Ltd (HKPD) invested $70K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Cellyan Biotechnology Co Ltd's current ratio?
Cellyan Biotechnology Co Ltd (HKPD) had a current ratio of 2.99 as of fiscal year 2025, which is generally considered healthy.
What is Cellyan Biotechnology Co Ltd's debt-to-equity ratio?
Cellyan Biotechnology Co Ltd (HKPD) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cellyan Biotechnology Co Ltd's return on assets (ROA)?
Cellyan Biotechnology Co Ltd (HKPD) had a return on assets of -0.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cellyan Biotechnology Co Ltd's P/E ratio?
Cellyan Biotechnology Co Ltd (HKPD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $6.8M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cellyan Biotechnology Co Ltd's price-to-sales ratio?
Cellyan Biotechnology Co Ltd (HKPD) trades at 0.3x sales, its market capitalization divided by revenue of $20.3M revenue, FY2025. The market capitalization is $6.8M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cellyan Biotechnology Co Ltd's Piotroski F-Score?
Cellyan Biotechnology Co Ltd (HKPD) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cellyan Biotechnology Co Ltd's earnings high quality?
Cellyan Biotechnology Co Ltd (HKPD) reported a net loss of $27K while generating $569K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cellyan Biotechnology Co Ltd?
Cellyan Biotechnology Co Ltd (HKPD) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.